Loading
AL-433 is an experimental small molecule from Alaw Therapeutics, in preclinical development for solid tumours.
AL-433 is a small molecule from Alaw Therapeutics. A selective, brain-penetrant CDK4 inhibitor engineered for selectivity over CDK6, intended to reduce CDK6-related blood toxicity; it targets tumours driven by the CDK4-cyclin D1-Rb-E2F axis. Its furthest stage is preclinical development, for solid tumours (indication not specified). No clinical trial naming it is registered on ClinicalTrials.gov. Nominated as a development candidate on 29 May 2026; first-in-human studies planned for the fourth quarter of 2026. No registered trial found. It has not been shown to work in people.
A selective, brain-penetrant CDK4 inhibitor engineered for selectivity over CDK6, intended to reduce CDK6-related blood toxicity; it targets tumours driven by the CDK4-cyclin D1-Rb-E2F axis.
1.AL-433 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AL-433" OR ABSTRACT:"AL-433") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AL-433, not a curated reading list.
Shares Alaw Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alaw Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/